BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC

Christine Lovly, MD, PhD, shares data on BDTX-1535, a “masterkey” EGFR inhibitor targeting classical, non-classical, and the C797S resistance mutation in patients with EGFR mutant non-small cell lung cancer (NSCLC), from a presentation at AACR 2024.

Related Content:

Rapid ReadoutsLung Cancer

OncLive’s September Roundup of Key FDA Approvals in Oncology

Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC

FDA Approves Perioperative Nivolumab for Resectable NSCLC